Skip to main content Skip to main navigation menu Skip to site footer

CD 105 As Prognostic Factors in Advanced Stage Breast Cancer Patients



Abstract

Background: Breast cancer is the most common cancer found in women worldwide. In 2012, more than 50% of breast cancer patients in Cipto Mangunkusumo Hospital were advanced breast cancer patients. Stage 3 breast cancer patients have five years’ survival rate by 72%, while who’s in stage 4 only by 22% even after receiving adequate treatment. It is said that only CD105, which specifically describes the intratumoral angiogenesis occurrences. Methods: A retrospective cohort analytic data from patient medical records Dharmais Cancer Hospital from 2011-2014 were studied. A simple random sampling and obtained a total of 32 patients. Statistical analysis was performed using univariate and multivariate analysis SPSS version 17.0 and medcalc. Results: The expression between CD105 with the survival rate is: crude HR 1.724 (95% CI 0.693 to 4.288) p=0.241. The median survival of the CD105 positive group is higher than the negative group. The relationship between CD105 groups Luminal A, therapy, and metastasis, the group with negative CD105 expression had a higher survival rate. There was a significant relationship between CD105 and clinicopathologic of breast cancer patients from age and CD105 expression (p=0.034). 71.8% of patients with HER2 negative, has a negative CD105 as well, and 60% of subjects with HER2-positive, suggesting that CD105 expression was also positive. Conclusion: CD105 can not be used as a prognostic factor in patients with advanced stage breast cancer, high CD105 patients have a lower survival compared with low or negative CD105 patients, and CD105 expression correlated with age and PR.

Keywords: advanced stage breast cancer CD105 prognostic factors survival rate of breast cancer angiogenesis marker

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, dkk. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Diunduh dari http://globocan.iarc.fr, pada 1 September 2015
  2. American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta: American Cancer Society, Inc. 2013.
  3. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med 2014;11:101-115.
  4. WHO. Breast cancer: prevention and control. Diunduh dari http://www.who.int/cancer/detection/breastcancer/en/ pada 1 September 2015
  5. Shenkier T, Weir L, Levine M, Olivotto I, Whelan T, Reyno L; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ. (march 2004) 170(6):983-94.
  6. Cheng ES, Jaafar H, Sharif SET. Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist’s Perspective. Pathology Research International Vol.2011 (2011), article ID 572706; 2011.
  7. Rau KM, Huang CC, Chiu TJ, Chen YY, Lu CC, Liu CT, et. al. Neovascularization Evaluated by CD105 Correlates Well with Prognostic Factors in Breast Cancers. Experimental and Therapeutic Medicine 4: 231-236, 2012.
  8. Duff SE, Li C, Garland JM, Kumar S. CD105 is Important for Angiogenesis: Evidence and Potential Application. FASEB J. 17, 984 – 992; 2003.
  9. Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, et al. Endoglin (CD105): A Review of its Role in Angiogenesis and Tumor Diagnosis, Progression And Therapy. Anticancer Research 31: 2283-2290 (2011)
  10. Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. Oncogene (2008) 27, 3567–3575
  11. Hartobagyi GN. Buzdar AU. Locally Advanced Breast Cancer. In Textbook of Breast Cancer A Clinical Guide to Therapy. Ed. Banodanna, Hartobagyi, Giani, 1997
  12. Ahn Se Hyun. Nation Wide Korean Breast Cancer Data 2000. The 3rd Biennial Meeting of the Asian Breast Cancer society. Seoul, Korea 2002
  13. Burke HB, Hutter RVP, Henson DE. Breast Carcinoma. Dalam Hermanek P, Gospodarowicz MK, Henson DE, Hutter RYP, Sobin LH [Ed]. Prognostic Factors in Cancer. New Delhi: Thomson Press. 1995. H 165-176
  14. Page DL and Jensen RA. Angiogenesis in Human Breast Carcinoma: What is The Question? Hum. Pathol. 26, 1173 – 1174; 1995
  15. Lindmark G, Gerdin B, Sandberg G, Pahlman L, Bergstorm R, Glimelius B. Prognostic Significance of The Microvascular Count in Colorectal Cancer. J. Clin. Oncol. 14, 461 – 466; 1996
  16. Gluz O, Wild P, Liedtke C, Kates R, Mendrik H, Ehm E, dkk. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial. Breast Cancer Res Treat (2011) 126:643–651
  17. Duff SE, LiC, GarlandJM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 17, 984–992 (2003)
  18. Fonsatti E, Altomonte M, Arslan P, Maio M. CD105 (CD105): a target for anti-angiogenetic cancer therapy. Current Drug Targets, 2003, 4, 291-296
  19. Kumar S, Ghellal A, Li C. Breast Carcinoma: Vascular Density Determined Using CD105 Antibody Correlates with Tumor Prognosis. Cancer Res 1999;59:856-861.
  20. Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, dkk. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol (2010) 2(2) 125-148
  21. Beketic-Oreskovic L, Ozretic P, Rabbani ZN, Jackson IL, Sarcevic B, Levanat S, dkk. Prognostic Significance of Carbonic Anhydrase IX (CA-IX), Endoglin (CD105) and 8-hydroxy-2′-deoxyguanosine (8-OHdG) in Breast Cancer Patients. Pathol. Oncol. Res. (2011) 17:593–603
  22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargente D, Ford R, dkk. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal Of Cancer 45 (2009) 228 –247
  23. Aryandono T. Survival from Operable Breast Cancer: Prognostic Factors in Yogyakarta, Indonesia. Asian Pacific Journal of Cancer Prevention, 2006. Pp.7(3):451-454.
  24. Hisham AN and Yip CH. Overview of Breast Cancer in Malaysian Women: A Problem with Late Diagnosis. Medline; 2006. 27(7):130-3
  25. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D. Global Cancer Statistics. CA Cancer J Clin., 2011, 61(2): 69-90
  26. Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coerbergh JWW. An Overview of Prognostic Factors for Long-Term Survivors of Breast Cancer. Breast Cancer Res Treat. 2008 Feb; 107(3): 309-330.
  27. Anaise D. Factors for Breast Cancer Prognosis and Survival. Diunduh dari www.danaise.com/prognostic-factors-for-breast-cancer-survival/?cat=5
  28. Kurian AW, Lichtensztajn DY, Keegan THM, Nelson DO, Clarke CA, and Gomez SL. Use of and Mortality After Bilateral Mastectomy Compared with Other Surgical Treatment for Breast Cancer in California, 1998 – 2011. JAMA. 2014;312(9):904-914.doi:10.1001/jama.2014-10707.
  29. Arriagada R, Le MG, Dunant A et al (2006) Twenty-five years of follow-up in patients with operable breast carcinoma: correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer 106:743–750
  30. Tripsianis G, Papadopoulou E, Romanidis K, Katotomichelakis M, Anagnostopoulos K, Kontomanolis E, et. al. Overall Survival and Clinicopathological Characteristics of Patients with Breast Cancer in Relation to the Expression Pattern of HER-2, IL-6, TNF-α, and TGF-β1. Asian Pac J Cancer Prev. 2013;14(11):6813-20.
  31. Park D, Karesen R, Noven T, and Sauer T. Ki-67 Expression in Primary Breast Carcinomas and Their Axillary Lymph Node Metastases: Clinical Implication. Virchows Arch DOI: 10.1007/s00428-007-0435-2(2007).
  32. Inwald. EC, Schalke MK, Hofstadter F, Zeman F, Koller, M, Gertstenhauer M, et. al. Ki-67 is A Prognostic Parameter in Breast Cancer Patients: Results of a Large Population-based Cohort of a Cancer Registry. Breast Cancer Res Treat (2013) 139:539-552
  33. Li B, Zhu Z, Wang J, Hou J, Zhao J, et al. (2004) Expression Correlation of Ki67 to P53,VEG F,and C-erbB-2 Genes in Breast Cancer and Their ClinicaI Significances, Chinese Journal of Cancer, 2004, 23(10), 1176–1179. Expression Correlation of Ki67 to P53, VEG F, and C-erbB-2 Genes in Breast Cancer and Their ClinicaI Significances, Chinese Journal of Cancer, 2004, 23(10), 1176– 1179 23: 1176–1179.
  34. Li F, Wu S, Xhou J, Sun J,Lin Q, Lin H, et. al. Prognostic Value of Ki-67 in Breast Cancer Patients with Positive Axillary Lymph Nodes: A Retrospective Cohort Study. PLOS One February 2014, vol. 9(2). E87264
  35. Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Meyer L, Ramuz O, et. al. CD105 Expression Is a Marker of High Metastatic Risk and Poor Outcome in Breast Carcinomas: Correlation Between Immunohistochemical Analysis and Long-Term Follow-up in a Series of 929 Patients. Am J Clin Pathol 2003;119:374-380 DOI: 10.1309/1KF54L6RB625556W
  36. Martinez LM, Labovsky V, Calcagno MdL, Davies KM, Rivello HG, Bianchi MS, et. al. CD105 Expression on CD34-Negative Spindle-Shaped Stromal Cells of Primary Tumor Is an Unvavorable Prognostic Marker in Early Breast Cancer Patients. PLoS One. 2015; 10(3): e0121421.
  37. Esquer FG, Agudo D, Arribas FM, Vilar MJN, and Schneider J. mRNA Expression of the Angiogenesis Markers VEGF and CD105 (Endoglin) in Human Breast Cancer. Anticancer Research May – June 2004 vol. 24 no. 3A 1581 – 86.
  38. Charpin C, Dales JP, Garcia S, Carpentier S, Djemli A, Andrac L, et al. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res. 2004; 10: 5815–5819. doi: 10.1158/1078-0432.CCR-04-0021
  39. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 2000;89: 122–126. doi: 10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M
  40. Dales JP, Garcia S, Andrac L, Carpentier S, Ramuz O, Lavaut MN, et al. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int J Oncol. 2004; 24: 1197–1204
  41. Roura S, Farre J, Botija CS, Llach A, Madsen LH, Cairo JJ, et. al. Effect of Aging on the Pluripotent Capacity of Human CD105+ Mesenchimal Stem Cells. European Journal of Heart Failure (Impact Factor: 6.53).11/2006; 8(6):555-63. DOI: 10.1016/j.ejheart.2005.11.006
  42. Vo MN, Evans M, Leitzel K, Ali SM, Wilson M, Demers L, et. al. Elevated Plasma Endoglin (CD105) Predicts Decreased Response and Survival in a Metastatic Breast Cancer Trial of Hormone Therapy. In Breast Cancer Res Treat (2010) 119:767-771. DOI 10.1007/s10549-008-0261-5

How to Cite

Hermansyah, D., Azdi Albar, Z., Joko Purwanto, D., Sari, L., & Putri, R. I. (2017). CD 105 As Prognostic Factors in Advanced Stage Breast Cancer Patients. Bali Medical Journal, 6(1), 227–235. https://doi.org/10.15562/bmj.v6i1.554
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
4

Total
19

Share

Search Panel

Dedy Hermansyah
Google Scholar
Pubmed
BMJ Journal

Zafiral Azdi Albar
Google Scholar
Pubmed
BMJ Journal

Denni Joko Purwanto
Google Scholar
Pubmed
BMJ Journal

Lenny Sari
Google Scholar
Pubmed
BMJ Journal

Risky Ifandriani Putri
Google Scholar
Pubmed
BMJ Journal